Evidence map›Paper›PMID 33893924›Full record

ReviewMolecular biology reports2021

Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.

Jun Lu, David Wood, Evan Ingley, Sulev Koks, Daniel Wong

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Liposarcoma: State of the Art-A Scoping Review.Medical sciences (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jun LuMedical School, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, 6009, Australia. jun.lu@research.uwa.edu.au.ORCID http://orcid.org/0000-0002-0411-8538
David WoodMedical School, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, 6009, Australia.
Evan IngleyCell Signalling Group, Harry Perkins Institute of Medical Research and Centre for Medical Research, The University of Western Australia, Perth, WA, 6009, Australia.
Sulev KoksPerron Institute for Neurological and Translational Science, Perth, WA, 6009, Australia.
Daniel WongAnatomical Pathology, PathWest, QEII Medical Centre, Perth, WA, 6009, Australia.
Murdoch University · AUThe University of Western Australia · AUQueen Elizabeth II Medical Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Well-differentiated liposarcoma (WDLPS) is the most frequent subtype of liposarcoma and may transform into dedifferentiated liposarcoma (DDLPS) which is a more aggressive subtype. Retroperitoneal lesions of WDLPS/DDLPS tend to recur repeatedly due to incomplete resections, and adjuvant chemotherapy and radiotherapy have little effect on patient survival. Consequently, identifying therapeutic targets and developing targeted drugs is critical for improving the outcome of WDLPS/DDLPS patients. In this review, we summarised the mutational landscape of WDLPS/DDLPS from recent studies focusing on potential oncogenic drivers and the development of molecular targeted drugs for DDLPS. Due to the limited number of studies on the molecular networks driving WDLPS to DDLPS development, we looked at other dedifferentiation-related tumours to identify potential parallel mechanisms that could be involved in the dedifferentiation process generating DDLPS.

Indexed as

Cell DedifferentiationGene Expression Regulation, NeoplasticHumansLiposarcomaMicroRNAsMutationMicroRNAsCell signallingDedifferentiated liposarcomaGenomic mutationMDM2 amplificationWell-differentiated liposarcoma

Identifiers

PMID33893924
OpenAlexW3156007826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.